StarMedTec

StarMedTec is a German company specializing in advanced medical solutions, particularly in the development of innovative laser therapy systems and devices for urological treatments. Founded in 2006 in Starnberg, Germany, StarMedTec focuses on creating advanced medical device technologies. The company was acquired by BayBG and S-Partner Kapital in August 2007, becoming a key player in the medical technology sector under their guidance. StarMedTec specializes in innovative medical solutions, focusing primarily on advanced laser therapy systems and lithotripsy devices aimed at treating benign prostatic hyperplasia (BPH) and urinary tract stones.

Their core product offerings include the GreenLight XPS™ Laser Therapy System, designed to redefine the standard of care for BPH by effectively reducing prostate size and alleviating urinary symptoms. Additional offerings feature the Lumenis Pulse™ series, notably the 120H Holmium Laser System equipped with MOSES™ Technology, enhancing efficiency in lithotripsy treatments, and the Rezūm™ Water Vapour Therapy System that utilizes convective water vapor energy to target obstructive tissue within the prostate. These products primarily serve healthcare professionals, including urologists and hospitals, across various geographical markets in Europe and other international regions. In 2018, StarMedTec reported an EBITDA of EUR 38,851.

2, while the revenue for the same year was EUR 0. StarMedTec plans to leverage recent funding to expand its product portfolio and geographical footprint. The company intends to launch new laser therapy devices targeting urological conditions by the end of 2024. Additionally, StarMedTec aims to enter new markets in Eastern Europe and Asia by 2025, enhancing its global presence.

The funding from the acquisition by BayBG and S-Partner Kapital will support these initiatives and drive growth in these strategic areas.